Advances in urinary protein biomarkers for urogenital and non-urogenital pathologies

Biochemia Medica

Volumn 25, Issue 1, 2015, Pages 22-35

  Pedroza Díaz, Johanna ^a   Röthlisberger, Sarah ^a  

^a INSTITUTO TECNOLÓGICO METROPOLITANO   (Colombia)

Author keywords

Biomarker; Protein; Urine

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALBUMIN; ALPHA 1 ANTITRYPSIN; ALPHA 1 MICROGLOBULIN; ALPHA2 GLYCOPROTEIN; ANTITHROMBIN III; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; BETA 2 MICROGLOBULIN; BETA ACTIN; BIOLOGICAL MARKER; CD59 ANTIGEN; CYSTEINE PROTEINASE INHIBITOR; EPHRIN RECEPTOR B4; FATTY ACID BINDING PROTEIN; FIBRINOGEN; FIBULIN; GELATINASE B; GELSOLIN; GLYCEROPHOSPHOINOSITOL INOSITOLPHOSPHODIESTERASE; HEMOGLOBIN ALPHA CHAIN; HISTONE H2B; MACROPHAGE ELASTASE; OSTEOPONTIN; PLASMA KALLIKREIN; RETINOL BINDING PROTEIN 4; SERINE PROTEINASE INHIBITOR; TAMM HORSFALL GLYCOPROTEIN; UNINDEXED DRUG; TUMOR MARKER;

ATHEROSCLEROSIS; BREAST CANCER; CAPILLARY ELECTROPHORESIS; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OSTEOARTHRITIS; PROSTATE CANCER; PROTEIN URINE LEVEL; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; UROGENITAL TRACT DISEASE; WESTERN BLOTTING; MEDLINE; NEOPLASM; PROTEINURIA; URINE;

ATHEROSCLEROSIS; DIABETES MELLITUS; HUMANS; NEOPLASMS; OSTEOARTHRITIS; PROTEINURIA; PUBMED; TUMOR MARKERS, BIOLOGICAL;

EID: 84922539794     PISSN: 13300962     EISSN: None     Source Type: Journal    
DOI: 10.11613/BM.2015.003     Document Type: Review

References (80)

1. Fang H, Wang K, Zhang J.Transcriptome and proteome analyses of drug interactions with natural products.Curr Drug Metab 2008;9:1038-48.http://dx.doi.org/10.2174/138920008786927802
2. Goo YA, Goodlett DR.Advances in proteomic prostate cancer biomarker discovery.J Proteomics 2010;73:1839-50.http://dx.doi.org/10.1016/j.jprot.2010.04.002
3. Xiao Z, Prieto D, Conrads TP, Veenstra TD, Issaq HJ.Proteomic patterns: their potential for disease diagnosis.Mol Cell Endocrinol 2005;230:95-106.http://dx.doi.org/10.1016/j.mce.2004.10.010
4. Omenn GS, States DJ, Adamski M, Blackwell TW, Menon R, Hermjakob H, et al.Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database.Proteomics 2005;5:3226-45.http://dx.doi.org/10.1002/pmic.200500358
5. Veenstra TD, Conrads TP, Hood BL, Avellino AM, Ellenbogen RG, Morrison RS.Biomarkers: mining the biofluid proteome.Mol Cell Proteomics 2005;4:409-18.http://dx.doi.org/10.1074/mcp.M500006-MCP200
6. Caubet C, Lacroix C, Decramer S, Drube J, Ehrich JH, Mischak H, et al.Advances in urinary proteome analysis and biomarker discovery in pediatric renal disease.Pediatr Nephrol 2010;25:27-35.http://dx.doi.org/10.1007/s00467-009-1251-5
7. Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P.Urine protein profiling with surface-enhanced laser-desorption/ ionization time-of-flight mass spectrometry.Kidney Int 2004;65:323-32.http://dx.doi.org/10.1111/j.1523-1755.2004.00352.x
8. Theodorescu D, Schiffer E, Bauer HW, Douwes F, Eichhorn F, Polley R, et al.Discovery and validation of urinary biomarkers for prostate cancer.Proteomics Clin Appl 2008;2:556-70.http://dx.doi.org/10.1002/prca.200780082
9. Gonzalez-Buitrago JM, Ferreira L, Lorenzo I.Urinary proteomics.Clin Chim Acta 2007;375:49-56.http://dx.doi.org/10.1016/j.cca.2006.07.027
10. Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M.The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins.Genome Biol 2006;7:R80.http://dx.doi.org/10.1186/gb-2006-7-9-r80
11. Thongboonkerd V, McLeish KR, Arthur JM, Klein JB.Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation.Kidney Int 2002;62:1461-9.http://dx.doi.org/10.1111/j.1523-1755.2002.kid565.x
12. Pieper R, Gatlin CL, McGrath AM, Makusky AJ, Mondal M, Seonarain M, et al.Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots.Proteomics 2004;4:1159-74.http://dx.doi.org/10.1002/pmic.200300661
13. Oh J, Pyo JH, Jo EH, Hwang SI, Kang SC, Jung JH, et al.Establishment of a near-standard two-dimensional human urine proteomic map.Proteomics 2004;4:3485-97.http:// dx.doi.org/10.1002/pmic.200401018
14. Thongboonkerd V, Malasit P.Renal and urinary proteomics: current applications and challenges.Proteomics 2005;5:1033-42.http://dx.doi.org/10.1002/pmic.200401012
15. Drake RR, White KY, Fuller TW, Igwe E, Clements MA, Nyalwidhe JO, et al.Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease.J Proteomics 2009;72:907-17.http://dx.doi.org/10.1016/j.jprot.2009.01.007
16. Casado-Vela J, Gomez del Pulgar T, Cebrian A, Alvarez-Ayerza N, Lacal JC.Human urine proteomics: building a list of human urine cancer biomarkers.Expert Rev Proteomics 2011;8:347-60.http://dx.doi.org/10.1586/epr.11.26
17. Maahs DM, Siwy J, Argiles A, Cerna M, Delles C, Dominiczak AF, et al.Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology.PLoS One 2010;5.http://dx.doi.org/10.1371/journal.pone.0013051
18. Good DM, Zurbig P, Argiles A, Bauer HW, Behrens G, Coon JJ, et al.Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease.Mol Cell Proteomics 2010;9:2424-37.http://dx.doi.org/10.1074/mcp.M110.001917
19. Kellum JA, Lameire N.Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1).Crit Care 2013;17:204.http://dx.doi.org/10.1186/cc11454
20. Lameire N, Kellum JA.Contrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary (Part 2).Crit Care 2013;17:205.http://dx.doi.org/10.1186/cc11455
21. Alebiosu CO, Ayodele OE.The global burden of chronic kidney disease and the way forward.Ethn Dis 2005;15:418-23
22. Barratt J, Feehally J.IgA nephropathy.J Am Soc Nephrol 2005;16:2088-97.http://dx.doi.org/10.1681/ASN.2005020134
23. Haubitz M, Wittke S, Weissinger EM, Walden M, Rupprecht HD, Floege J, et al.Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy.Kidney Int 2005;67:2313-20.http://dx.doi.org/10.1111/j.1523-1755.2005.00335.x
24. Graterol F, Navarro-Munoz M, Ibernon M, Lopez D, Troya MI, Perez V, et al.Poor histological lesions in IgA nephropathy may be reflected in blood and urine peptide profiling.BMC Nephrol 2013;14:82.http://dx.doi.org/10.1186/1471-2369-14-82
25. Prajczer S, Heidenreich U, Pfaller W, Kotanko P, Lhotta K, Jennings P.Evidence for a role of uromodulin in chronic kidney disease progression.Nephrol Dial Transpl 2010;25:1896-903.http://dx.doi.org/10.1093/ndt/gfp748
26. Navarro-Munoz M, Ibernon M, Bonet J, Perez V, Pastor MC, Bayes B, et al.Uromodulin and alpha(1)-antitrypsin urinary peptide analysis to differentiate glomerular kidney diseases.Kidney Blood Press Res 2012;35:314-25.http://dx.doi.org/10.1159/000335383
27. Ding H, He Y, Li K, Yang J, Li X, Lu R, et al.Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy.Clin Immunol 2007;123:227-34.http://dx.doi.org/10.1016/j.clim.2007.01.010
28. (IARC) IA for R on C.GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012.Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.Accessed August 16th 2014
29. Harvey P, Basuita A, Endersby D, Curtis B, Iacovidou A, Walker M.A systematic review of the diagnostic accuracy of prostate specific antigen.BMC Urol 2009;9:14.http:// dx.doi.org/10.1186/1471-2490-9-14
30. Bickers B, Aukim-Hastie C.New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era.Anticancer Res 2009;29:3289-98
31. Lazzeri M, Abrate A, Lughezzani G, Gadda GM, Freschi M, Mistretta F, et al.Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform (-2)proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination.Urology 2014;83:606-12.http://dx.doi.org/10.1016/j.urology.2013.10.016
32. Wu N, Liu S, Guo C, Hou Z, Sun MZ.The role of annexin A3 playing in cancers.Clin Transl Oncol 2013;15:106-10.http://dx.doi.org/10.1007/s12094-012-0928-6
33. Schostak M, Schwall GP, Poznanovic S, Groebe K, Muller M, Messinger D, et al.Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection.J Urol 2009;181:343-53.http://dx.doi.org/10.1016/j.juro.2008.08.119
34. M’Koma AE, Blum DL, Norris JL, Koyama T, Billheimer D, Motley S, et al.Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine.Biochem Biophys Res Commun 2007;353:829-34.http://dx.doi.org/10.1016/j.bbrc.2006.12.111
35. Soggiu A, Piras C, Bonizzi L, Hussein HA, Pisanu S, Roncada P.A discovery-phase urine proteomics investigation in type 1 diabetes.Acta Diabetol 2012;49:453-64.http://dx.doi.org/10.1007/s00592-012-0407-0
36. Brott DA, Adler SH, Arani R, Lovick SC, Pinches M, Furlong ST.Characterization of renal biomarkers for use in clinical trials: biomarker evaluation in healthy volunteers.Drug Des Devel Ther 2014;8:227-37.http://dx.doi.org/10.2147/ DDDT.S54956
37. Morgan R, Boxall A, Bhatt A, Bailey M, Hindley R, Langley S, et al.Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer.Clin Cancer Res 2011;17:1090-8.http://dx.doi.org/10.1158/1078-0432.CCR-10-2410
38. Killick E, Morgan R, Launchbury F, Bancroft E, Page E, Castro E, et al.Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men.Sci Rep 2013;3:2059.http://dx.doi.org/10.1038/srep02059
39. Pandha H, Sorensen KD, Orntoft TF, Langley S, Hoyer S, Borre M, et al.Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer.BJU Int 2012;110:E287-92.http://dx.doi.org/10.1111/j.1464-410X.2012.11208.x
40. Breast Cancer Facts & Figures 2013-2014.2014; Available from: http://www.cancer.org Accessed August 16th 2014
41. Tabar L, Vitak B, Chen TH-H, Yen AM-F, Cohen A, Tot T, et al.Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades.Radiology 2011;260:658-63.http://dx.doi.org/10.1148/radiol11110469.
42. 43 .Paci E.Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet.J Med Screen 2012;19 Suppl 1:5-13.http://dx.doi.org/10.1258/jms.2012.012077
43. Sturgeon CM, Duffy MJ, Stenman U-H, Lilja H, Brunner N, Chan DW, et al.National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.Clin Chem 2008;54:e11-79.http://dx.doi.org/10.1373/clinchem.2008.105601
44. Opstal-van Winden AWJ, Rodenburg W, Pennings JLA, van Oostrom CTM, Beijnen JH, Peeters PHM, et al.A bead-based multiplexed immunoassay to evaluate breast cancer biomarkers for early detection in pre-diagnostic serum.Int J Mol Sci 2012;13:13587-604.http://dx.doi.org/10.3390/ ijms131013587
45. Nolen BM, Lokshin AE.The advancement of biomarker-based diagnostic tools for ovarian, breast, and pancreatic cancer through the use of urine as an analytical biofluid.Int J Biol Markers.2011;26:141-52.http://dx.doi.org/10.5301/ JBM.2011.8613
46. Ham M, Moon A.Inflammatory and microenvironmental factors involved in breast cancer progression.Arch Pharm Res 2013;36:1419-31.http://dx.doi.org/10.1007/s12272-013-0271-7
47. Woodward JK, Holen I, Coleman RE, Buttle DJ.The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer.Bone 2007;41:912-27.http://dx.doi.org/10.1016/j.bone.2007.07.024
48. Pories SE, Zurakowski D, Roy R, Lamb CC, Raza S, Exarhopoulos A, et al.Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment.Cancer Epidemiol Biomarkers Prev 2008;17:1034-42.http://dx.doi.org/10.1158/1055-9965.EPI-07-0365
49. Kveiborg M, Frohlich C, Albrechtsen R, Tischler V, Dietrich N, Holck P, et al.A role for ADAM12 in breast tumor progression and stromal cell apoptosis.Cancer Res 2005;65:4754-61.http://dx.doi.org/10.1158/0008-5472.CAN-05-0262
50. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA.ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage.J Biol Chem 2004;279:51323-30.http://dx.doi.org/10.1074/jbc.M409565200
51. Nyren-Erickson EK, Bouton M, Raval M, Totzauer J, Mallik S, Alberto N.Urinary concentrations of ADAM 12 from breast cancer patients pre-and post-surgery vs.cancer-free controls: a clinical study for biomarker validation.J Negat Results Biomed 2014;13:5.http://dx.doi.org/10.1186/1477-5751-13-5
52. Iba K, Albrechtsen R, Gilpin BJ, Loechel F, Wewer UM.Cysteine-rich domain of human ADAM 12 (meltrin alpha) supports tumor cell adhesion.Am J Pathol 1999;154:1489-501.http://dx.doi.org/10.1016/S0002-9440(10)65403-X
53. Kanakis D, Lendeckel U, Theodosiou P, Dobrowolny H, Mawrin C, Keilhoff G, et al.ADAM 12: a putative marker of oligodendrogliomas? Dis Markers 2013;34:81-91.http://dx.doi.org/10.1155/2013/823025
54. Shao S, Li Z, Gao W, Yu G, Liu D, Pan F.ADAM-12 as a diagnostic marker for the proliferation, migration and invasion in patients with small cell lung cancer.PLoS One 2014;9:e85936.http://dx.doi.org/10.1371/journal.pone.0085936
55. Yan L, Borregaard N, Kjeldsen L, Moses MA.The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL).Modulation of MMP-9 activity by NGAL.J Biol Chem 2001;276:37258-65.http:// dx.doi.org/10.1074/jbc.M106089200
56. Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL, et al.Lipocalin 2 promotes breast cancer progression.Proc Natl Acad Sci U S A 2009;106:3913-8.http://dx.doi.org/10.1073/pnas.0810617106
57. Candido S, Maestro R, Polesel J, Catania A, Maira F, Signorelli SS, et al.Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer.Oncotarget 2014;5:1576-94
58. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, et al.Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery.Lancet 2005;365:1231-8.http://dx.doi.org/10.1016/S0140-6736(05)74811-X
59. Diagnosis and classification of diabetes mellitus.Diab Care 2010;33 Suppl 1:S62-9.http://dx.doi.org/10.2337/dc10-S062
60. Global guideline for type 2 diabetes.Diabetes Res Clin Pr.Available from: http://www.ncbi.nlm.nih.gov/ pubmed/24508150.Accessed August 16th 2014
61. Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, et al.Screening for type 2 diabetes: literature review and economic modelling.Heal Technol Assess 2007;11:iii-iv, ix-xi, 1-125
62. Snell-Bergeon JK, Maahs DM, Ogden LG, Kinney GL, Hokanson JE, Schiffer E, et al.Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease.Diabetes Technol Ther 2009;11:1-9.http://dx.doi.org/10.1089/dia.2008.0040
63. Hashemi M, Naderi M, Rashidi H, Ghavami S.Impaired activity of serum alpha-1-antitrypsin in diabetes mellitus.Diabetes Res Clin Pr 2007;75:246-8.http://dx.doi.org/10.1016/j.diabres.2006.06.020
64. Grant PJ.Diabetes mellitus as a prothrombotic condition.J Intern Med 2007;262:157-72.http://dx.doi.org/10.1111/ j.1365-2796.2007.01824.x
65. Caseiro A, Barros A, Ferreira R, Padrao A, Aroso M, Quintaneiro C, et al.Pursuing type 1 diabetes mellitus and related complications through urinary proteomics.Transl Res 2013;163:188-99.http://dx.doi.org/10.1016/j.trsl.2013.09.005
66. Lei T, Zhao X, Jin S, Meng Q, Zhou H, Zhang M.Discovery of potential bladder cancer biomarkers by comparative urine proteomics and analysis.Clin Genitourin Cancer 2013;11:56-62.http://dx.doi.org/10.1016/j.clgc.2012.06.003
67. Urquidi V, Goodison S, Ross S, Chang M, Dai Y, Rosser CJ.Diagnostic potential of urinary α1-antitrypsin and apolipoprotein E in the detection of bladder cancer.J Urol 2012;188:2377-83.http://dx.doi.org/10.1016/j.juro.2012.07.094
68. Von Zur Muhlen C, Schiffer E, Zuerbig P, Kellmann M, Brasse M, Meert N, et al.Evaluation of urine proteome pattern analysis for its potential to reflect coronary artery atherosclerosis in symptomatic patients.J Proteome Res 2009;8:335-45.http://dx.doi.org/10.1021/pr800615t
69. Barascuk N, Vassiliadis E, Larsen L, Wang J, Zheng Q, Xing R, et al.Development and validation of an enzyme-linked immunosorbent assay for the quantification of a specific MMP-9 mediated degradation fragment of type III collagen--A novel biomarker of atherosclerotic plaque remodeling.Clin Biochem 2011;44:900-6.http://dx.doi.org/10.1016/j.clinbiochem.2011.04.004
70. Adiguzel E, Ahmad PJ, Franco C, Bendeck MP.Collagens in the progression and complications of atherosclerosis.Vasc Med 2009;14:73-89.http://dx.doi.org/10.1177/1358863X08094801
71. Delles C, Schiffer E, von Zur Muhlen C, Peter K, Rossing P, Parving H-H, et al.Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals.J Hypertens 2010;28:2316-22.http://dx.doi.org/10.1097/HJH.0b013e32833d81b7
72. Von zur Muhlen C, Schiffer E, Sackmann C, Zurbig P, Neudorfer I, Zirlik A, et al.Urine proteome analysis reflects atherosclerotic disease in an ApoE-/-mouse model and allows the discovery of new candidate biomarkers in mouse and human atherosclerosis.Mol Cell Proteomics 2012;11:M111 013847
73. Troeberg L, Nagase H.Proteases involved in cartilage matrix degradation in osteoarthritis.Biochim Biophys Acta 2012;1824:133-45.http://dx.doi.org/10.1016/j.bbapap.2011.06.020
74. Smith GN.The role of collagenolytic matrix metalloproteinases in the loss of articular cartilage in osteoarthritis.Front Biosci 2006;11:3081-95.http://dx.doi.org/10.2741/2034
75. Nemirovskiy OV, Dufield DR, Sunyer T, Aggarwal P, Welsch DJ, Mathews WR.Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo.Anal Biochem 2007;361:93-101.http://dx.doi.org/10.1016/j.ab.2006.10.034
76. Nemirovskiy O, Li WW, Szekely-Klepser G.Design and validation of an immunoaffinity LC-MS/MS assay for the quantification of a collagen type II neoepitope peptide in human urine: application as a biomarker of osteoarthritis.Methods Mol Biol 2010;641:253-70.http://dx.doi.org/10.1007/978-1-60761-711-2_15
77. Henrotin Y, Gharbi M, Mazzucchelli G, Dubuc JE, De Pauw E, Deberg M.Fibulin 3 peptides Fib3-1 and Fib3-2 are potential biomarkers of osteoarthritis.Arthritis Rheum 2012;64:2260-7.http://dx.doi.org/10.1002/art.34392
78. Klenotic PA, Munier FL, Marmorstein LY, Anand-Apte B.Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1).Implications for macular degenerations.J Biol Chem 2004;279:30469-73.http://dx.doi.org/10.1074/jbc.M403026200
79. Kevorkian L, Young DA, Darrah C, Donell ST, Shepstone L, Porter S, et al.Expression profiling of metalloproteinases and their inhibitors in cartilage.Arthritis Rheum 2004;50:131-41.http://dx.doi.org/10.1002/art.11433
80. Van Spil WE, Jansen NW, Bijlsma JW, Reijman M, DeGroot J, Welsing PM, et al.Clusters within a wide spectrum of biochemical markers for osteoarthritis: data from CHECK, a large cohort of individuals with very early symptomatic osteoarthritis.Osteoarthr Cartil 2012;20:745-54.http:// dx.doi.org/10.1016/j.joca.2012.04.004